304 related articles for article (PubMed ID: 31613314)
21. κ Opioid receptor activation in different brain regions differentially modulates anxiety-related behaviors in mice.
Wang YJ; Hang A; Lu YC; Long Y; Zan GY; Li XP; Wang Q; Zhao ZX; He L; Chi ZQ; Liu JG
Neuropharmacology; 2016 Nov; 110(Pt A):92-101. PubMed ID: 27106167
[TBL] [Abstract][Full Text] [Related]
22. Sodium channel blocking actions of the kappa-opioid receptor agonist U50,488 contribute to its visceral antinociceptive effects.
Su X; Joshi SK; Kardos S; Gebhart GF
J Neurophysiol; 2002 Mar; 87(3):1271-9. PubMed ID: 11877501
[TBL] [Abstract][Full Text] [Related]
23. Age-related differences in sensitivity to the antinociceptive effects of kappa opioids in adult male rats.
Smith MA; French AM
Psychopharmacology (Berl); 2002 Jul; 162(3):255-64. PubMed ID: 12122483
[TBL] [Abstract][Full Text] [Related]
24. Mu and kappa opioid receptor agonists antagonize icilin-induced wet-dog shaking in rats.
Werkheiser JL; Rawls SM; Cowan A
Eur J Pharmacol; 2006 Oct; 547(1-3):101-5. PubMed ID: 16945367
[TBL] [Abstract][Full Text] [Related]
25. Behavioural effect of pretreatment with opioid antagonists and sigma binding site ligands on the abnormal motor response produced by the kappa opioid agonist U50,488H in guinea pigs.
Brent PJ
Neuropharmacology; 1993 Aug; 32(8):751-60. PubMed ID: 8413839
[TBL] [Abstract][Full Text] [Related]
26. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
Wilson JL; Nayanar V; Walker JS
Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
[TBL] [Abstract][Full Text] [Related]
27. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
28. Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.
Ko MC; Johnson MD; Butelman ER; Willmont KJ; Mosberg HI; Woods JH
J Pharmacol Exp Ther; 1999 Dec; 291(3):1113-20. PubMed ID: 10565831
[TBL] [Abstract][Full Text] [Related]
29. Enhanced sensitivity to the antinociceptive effects of kappa opioids in naltrexone-treated rats: dose- and time-dependent effects.
Smith MA; McClean JM; Greene JL
Behav Pharmacol; 2003 Dec; 14(8):641-7. PubMed ID: 14665981
[TBL] [Abstract][Full Text] [Related]
30. kappa-Opioid receptor stimulation inhibits augmentation of Ca(2+) transient and hypertrophy induced by isoprenaline in neonatal rat ventricular myocytes - Role of CaMKIIdelta(B).
Wu G; Wang H; Yang J; Yang Y; Liu C; Jing L; Wong TM
Eur J Pharmacol; 2008 Oct; 595(1-3):52-7. PubMed ID: 18721804
[TBL] [Abstract][Full Text] [Related]
31. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
Jackson KJ; Jackson A; Carroll FI; Damaj MI
Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637
[TBL] [Abstract][Full Text] [Related]
32. Chronic muscle pain induced by repeated acid Injection is reversed by spinally administered mu- and delta-, but not kappa-, opioid receptor agonists.
Sluka KA; Rohlwing JJ; Bussey RA; Eikenberry SA; Wilken JM
J Pharmacol Exp Ther; 2002 Sep; 302(3):1146-50. PubMed ID: 12183674
[TBL] [Abstract][Full Text] [Related]
33. Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
Jackson KJ; Carroll FI; Negus SS; Damaj MI
Psychopharmacology (Berl); 2010 Jun; 210(2):285-94. PubMed ID: 20232057
[TBL] [Abstract][Full Text] [Related]
34. The discriminative stimulus properties of U50,488 and morphine are not shared by fedotozine.
Broqua P; Wettstein JG; Rocher MN; Rivière PJ; Dahl SG
Eur Neuropsychopharmacol; 1998 Dec; 8(4):261-6. PubMed ID: 9928914
[TBL] [Abstract][Full Text] [Related]
35. Trial-selective effects of U50,488H, a kappa-opioid receptor agonist, on consummatory successive negative contrast.
Wood MD; Norris JN; Daniel AM; Papini MR
Behav Brain Res; 2008 Nov; 193(1):28-36. PubMed ID: 18514923
[TBL] [Abstract][Full Text] [Related]
36. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
37. Effects of the long-lasting kappa opioid 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl) ethyl] acetamide in a drug discrimination and warm water tail-withdrawal procedure.
Terner JM; Lomas LM; Lewis JW; Husbands SM; Picker MJ
Behav Pharmacol; 2005 Dec; 16(8):665-70. PubMed ID: 16286819
[TBL] [Abstract][Full Text] [Related]
38. Schild (apparent pA2) analysis of a kappa-opioid antagonist in Planaria.
Raffa RB; Baron DA; Tallarida RJ
Eur J Pharmacol; 2006 Jul; 540(1-3):200-1. PubMed ID: 16737694
[TBL] [Abstract][Full Text] [Related]
39. Antidepressant-like effects of dezocine in mice: involvement of 5-HT1A and κ opioid receptors.
Shang L; Duan C; Chang S; Chang N; Jia S
Behav Pharmacol; 2021 Sep; 32(6):472-478. PubMed ID: 34101632
[TBL] [Abstract][Full Text] [Related]
40. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats.
Todtenkopf MS; Marcus JF; Portoghese PS; Carlezon WA
Psychopharmacology (Berl); 2004 Apr; 172(4):463-70. PubMed ID: 14727002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
